Add BrightSurf on Google Email

Search results for “Ebola”

1,000+ results for "Ebola"

The Lancet Infectious Diseases: Experimental post-exposure antiviral treatment may protect humans from Ebola virus

A case-series of eight British healthcare workers who received antiviral-based therapies after possible accidental exposure to Ebola virus in Sierra Leone did not develop the disease. The study suggests that post-exposure prophylaxis may be effective in preventing Ebola infection, and authors call for standardised guidelines to be deve...

SourceThe Lancet·JournalThe Lancet Infectious Diseases·DateAug 25, 2015

How can we improve data sharing of biomedical research across the globe?

A special issue of Journal of Empirical Research on Human Research Ethics presents guidelines, protocols, models, and resources for improving data sharing in low- and middle-income settings. Researchers found varying concerns and challenges across five countries, but most agreed that data sharing is crucial for scientific progress.

SourceSAGE·JournalJournal of Empirical Research on Human Research Ethics·DateAug 21, 2015

Antiviral compound protects nonhuman primates against Marburg virus

A study published in The New England Journal of Medicine reports that an experimental compound, AVI-7288, protected nonhuman primates against the deadly Marburg virus. The compound showed efficacy even when administered after exposure to the virus. Phase I clinical trial results also indicated safety and tolerability.

SourceUS Army Medical Research Institute of Infectious Diseases·JournalNew England Journal of Medicine·DateJul 22, 2015

Ebola vaccine trial begins in Senegal

A clinical trial testing an Ebola vaccine developed on a new cell line is underway in Senegal, aiming to provide a rapid response to outbreaks. The trial uses two vaccines, ChAd3-EBO Z and MVA-EBO Z, which have shown excellent safety profiles and promise for low-cost mass production.

Could dissolvable microneedles replace injected vaccines?

A new vaccine patch made of dissolvable material has been shown to be effective in protecting against flu infection, with an immune reaction equal to or stronger than traditional needle-delivered vaccines. The patch is easy to use without medical personnel, making it ideal for developing countries.

SourceElsevier·JournalBiomaterials·DateJul 14, 2015

Viral protein in their sights

A team from Harvard Medical School has revealed the atomic level structure of VSV polymerase protein L, a key component in RNA virus replication. This finding provides insights into how these viruses copy their genomes inside host cells.

SourceHarvard Medical School·JournalCell·DateJul 2, 2015

Rapid Ebola diagnostic successful in field trial

A new rapid diagnostic test has been shown to accurately diagnose Ebola virus disease within minutes, revolutionizing treatment and containment. The test's sensitivity and specificity rates are comparable to laboratory-based methods, offering a promising solution to the challenges of early diagnosis and timely intervention.

SourceHarvard Medical School·JournalThe Lancet·DateJun 25, 2015

Three Ebola virus variants identified in Guinea

Scientists at the Institut Pasteur sequenced three distinct Ebola virus variants co-circulating in Guinea, with each variant defined by unique mutations affecting viral proteins. The study highlights the genetic diversity of the viruses circulating in Guinea during the epidemic's spread and will aid in optimizing treatments and vaccines.

SourceInstitut Pasteur·JournalNature·DateJun 24, 2015

Shining a stochastic spotlight on Ebola

Engineers at Lehigh University are developing stochastic models to study the dynamics of Ebola virus infection in bats and its potential human transmission. The goal is to quantify the risk associated with the virus's spread and provide a basis for resource allocation and epidemic response strategies.

Sequencing Ebola's secrets

A global team has sequenced over 200 Ebola virus genomes to capture the fullest picture yet of how the virus is transmitted and changes over time. The study reveals that cross-border transmission played a smaller role in the outbreak than previously thought, and that the virus has begun to weed out mutations that do not benefit it.

SourceHarvard University·JournalCell·DateJun 18, 2015

Australian researcher helps with Ebola vaccine trials

A team of researchers, led by Dr. Steve Bellan and including Associate Professor Manoj Gambhir from Monash University, have identified the most effective human trial design for testing Ebola vaccines in Sierra Leone. The study suggests that a modified randomized control trial is the best approach to detect an effective and safe vaccine.

SourceMonash University·JournalThe Lancet Infectious Diseases·DateMay 18, 2015

Damming and damning hemorrhagic diseases

Scientists at the University of Montreal discover that a protein in the Rift Valley fever virus mimics human DNA repair factors, making it vulnerable to drug therapy. This breakthrough could lead to new treatments for deadly tropical infections such as Ebola.

SourceUniversity of Montreal·JournalProceedings of the National Academy of Sciences·DateMay 10, 2015

The Lancet: Can the Ebola outbreak rejuvenate global health security?

The west African Ebola epidemic has sparked interest in global health security, but its impact on political commitment to public health is uncertain. The crisis has highlighted the importance of securing individuals' access to healthcare as part of global health security. Key challenges include counterfeit medicines, antimicrobial resi...

SourceThe Lancet·JournalThe Lancet·DateMay 7, 2015

Insight into the Ebola virus nucleocapsid assembly mechanism

Researchers solved the structure of Ebola virus nucleoprotein core domain to 1.8 Å resolution, revealing RNA binding groove similarities with other viral NPs. The findings provide valuable insights into EBOV genome assembly and transcription mechanism, as well as potential antiviral therapies targeting RNP formation.

SourceSpringer·JournalProtein & Cell·DateMay 6, 2015